Anti–Vascular Endothelial Growth Factor and Panretinal Photocoagulation Use after Protocol S for Proliferative Diabetic Retinopathy
- 1 February 2021
- journal article
- conference paper
- Published by Elsevier in Ophthalmology Retina
- Vol. 5 (2) , 151-159
Abstract
No abstract availableKeywords
Funding Information
- Stanford University School of Medicine
This publication has 23 references indexed in Scilit:
- American Society of Retina Specialists Clinical Practice Guidelines: Management of Nonproliferative and Proliferative Diabetic Retinopathy Without Diabetic Macular EdemaJournal of Vitreoretinal Diseases, 2020
- Diabetic Retinopathy Preferred Practice Pattern®Ophthalmology, 2020
- A Multinational Comparison of Anti–Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-PacificOphthalmology Retina, 2019
- Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic RetinopathyJAMA Ophthalmology, 2017
- Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage PatientsOphthalmology, 2017
- Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic RetinopathyJAMA, 2015
- Diabetic retinopathyThe Lancet, 2010
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- Photocoagulation for Diabetic Macular EdemaArchives of Ophthalmology (1950), 1985
- Preliminary Report on Effects of Photocoagulation TherapyAmerican Journal of Ophthalmology, 1976